Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia

Hereditary hemorrhagic telangiectasia (HHT) is a disease characterized by mucocutaneous telangiectasias and visceral arteriovenous malformations. The genetic mutations that cause this disease result in elevated levels of vascular endothelial growth factor, which is inhibited by bevacizumab. Previous...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Andrew B., Ross, Douglas A., Berard, Paul, Figueroa-Bodine, Jaszmin, Livada, Nancy, Richer, Sara L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OceanSide Publications, Inc. 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124584/
https://www.ncbi.nlm.nih.gov/pubmed/25199101
http://dx.doi.org/10.2500/ar.2014.5.0091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124584/
https://www.ncbi.nlm.nih.gov/pubmed/25199101
http://dx.doi.org/10.2500/ar.2014.5.0091

Ejemplares similares